Panaphix

Panaphix is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for neuropsychiatric and inflammatory disorders. The company's lead candidate, PAX-101, is a first-in-class oral cytokine modulator designed to cross the blood-brain barrier and inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. By targeting neuroinflammation, Panaphix aims to provide a new treatment paradigm for patients with major depressive disorder and treatment-resistant depression who do not respond to traditional monoamine-based antidepressants. The company is currently advancing its pipeline through Phase 2 clinical trials to validate the efficacy of its anti-inflammatory approach in mental health.